Mapping Fibrogenic Cascades Across Organs to Define Where Fibrosis Converges & When to Intervene
8:31 am - Tuesday 1st December 2026
Fibrosis begins through different organ-specific injuries, but many pathways may
converge around fibroblast activation, immune-stromal crosstalk, mechanotransduction,
ECM remodeling, and failed repair. This workshop will compare fibrogenic cascades
across lung, liver, kidney, gut, and skin to determine where fibrosis becomes targetable,
when intervention is most likely to succeed, and whether mechanisms support panfibrotic or indication-specific strategies.
Discussion Topics Include:
- Mapping common downstream fibrotic pathways involving fibroblast activation, ECM deposition, and mechanotransduction across organs
- Understanding organ-specific inciting injuries, epithelial responses, and immune microenvironments that drive early disease
- How spatial omics, niche-specific activation cues, and cross-organ learnings are enabling more precise, safer antifibrotic strategies
- Determining at which disease stage cross-indication therapeutic approaches become most viable versus requiring tissue-specific targeting
